Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PMA (pre-market approval) supplement expands Nidek's PKRr (photorefractive keratectomy) therapy:

This article was originally published in Clinica

Executive Summary

Nidek has received a premarket approval supplement from the US FDA to expand the use of its photorefractive keratectomy laser system to treat patients who have moderate myopia with astigmatism. The EC-5000 system, which is already approved for reducing or eliminating myopia ranging in severity from 0.75 to 13.00 dioptres, can now be used to treat myopia ranging from 1.00 to 8.00 dioptres with refractive astigmatism ranging between 0.50 and 4.00 dioptres cylinder by manifest refraction. The Japanese company, which has US operations in Fremont, California, also received FDA clearance for its MK-2000 keratome system for use during lamellar procedures.

You may also be interested in...



Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

People On The Move: Appointments At Stada, PGEU, And UK Health Claims Committee

Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.

Topics

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel